Tagged with M

France Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care pathways and the hot trend of digitalization. Lala goes on to assess France’s willingness and capability to embrace this technology,…

Spain Maria Vila, regional vice-president for Spain and Portugal at Medtronic, highlights how she managed the integration of Covidien in Europe and where Medtronic stands today in Spain. Furthermore, she highlights the challenges of introducing new technology in Spain and how the company is shifting to becoming not only a solutions…

Germany Peter Homberg of Dentons Germany examines the regulatory status quo around the free sale of products containing cannabidiol (CBD) across Europe. Although deregulation efforts are underway, Homberg argues that the trade in these products is not as free and unregulated as it may initially seem.   CBD products that are…

Rankings A new report from specialist pharma and biotech consultancy Novasecta explores how the world’s top 100 pharma companies are shaping the future of healthcare. Through an examination of the various business models and key value drivers being applied by the top 100, a picture emerges of the successful modern pharma…

Rankings A new report from specialist pharma and biotech consultancy Novasecta explores how the world’s top 100 pharma companies are shaping the future of healthcare. Novasecta’s Global 100 is based on total group revenues (2018) of all organisations that have pharmaceutical interests, with the aim of benchmarking industry performance in its fullest context.    …

France Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable recent growth, and the state of play for SMEs in France today.   We as a flexible medium-sized company have…

Spain Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset of doctors. Furthermore, he touches on the company’s international strategy and the importance of a personalized care approach.   Our…

France Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products…

Korea Shin Poong is one of the oldest pharmaceutical companies in Korea. Established after the Korean War, the company’s original mission was to provide high-quality and affordable generic medicines to the Korean people. Now the company has transitioned into an innovative developer of novel first-in-class therapeutics, including a malaria treatment on…

France Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to comment on Biogaran’s unique strategy of leveraging added solutions, international expansion, and biosimilars. He concludes with his thoughts on the…

Malaysia Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.   For the time being, the outlook for the private sector, including for pharmaceutical firms, is good Another populist government,…

Korea Cure Therapeutics is a startup developing gene and cell therapies in Korea. Its founder David Kim explains where his passion for regenerative therapies stems from, breaks down the main hurdles standing in the way of success and describes how his company’s business model focused on flexibility and development speed through…